Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

A1237

Sigma-Aldrich

Pramipexole dihydrochloride

>98% (HPLC), powder

Sinônimo(s):

(S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride, PPX dihydrochloride

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C10H17N3S · 2HCl
Número CAS:
Peso molecular:
284.25
Número MDL:
Código UNSPSC:
51111800
ID de substância PubChem:
NACRES:
NA.77

Ensaio

>98% (HPLC)

forma

powder

condição de armazenamento

desiccated

cor

white to off-white

solubilidade

H2O: >20 mg/mL

originador

Boehringer Ingelheim

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

Cl.Cl.CCCN[C@H]1CCc2nc(N)sc2C1

InChI

1S/C10H17N3S.2ClH/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H/t7-;;/m0../s1

chave InChI

QMNWXHSYPXQFSK-KLXURFKVSA-N

Informações sobre genes

Descrição geral

Pramipexole belongs to non-ergoline class and is derived from benzothiazole. It has strong affinity for D2 and D3 receptors (dopamine receptors) compared to other ergoline-derived drugs. However, it does not associate with non-dopamine receptors, for instance adrenergic and serotonin receptors.

Aplicação

Pramipexole dihydrochloride has been used as D2 receptor agonist in dopamine (DA)-depleted striatum slices.
Pramipexole dihydrochloride has been used as a D2-like DR (dopaminergic receptor) agonist in study associated with Parkinson′s disease. It has also been used as a D2/D3 receptor agonist to study risky decision-making in rats.

Ações bioquímicas/fisiológicas

Pramipexole elicits neuroprotective role and may help in treating depression. It also has a potential to modulate limb movement and may be effective in treating restless legs syndrome.
Pramipexole is a dopamine agonist active at D3 and D2 receptor subtypes. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways.
Pramipexole is a therapeutic agent for Parkinson′s disease and restless leg syndrome. It also exhibits antidepressant responses in patients suffering from MDD (major depressive disorder) and bipolar depression.

Características e benefícios

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Exclamation mark

Palavra indicadora

Warning

Frases de perigo

Classificações de perigo

Acute Tox. 4 Oral - STOT SE 3

Órgãos-alvo

Central nervous system

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 2

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Doble M
Drug Design null
Esther Lara-González et al.
Neuroscience, 410, 76-96 (2019-05-13)
Parkinson's disease (PD) is a neurodegenerative illness presenting motor and non-motor symptoms due to the loss of dopaminergic terminals in basal ganglia, most importantly, the striatum. L-DOPA relieves many motor signs. Unfortunately, in the long term, L-DOPA use causes motor
Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
Jan Fawcett et al.
The American journal of psychiatry, 173(2), 107-111 (2016-02-06)
William Winlow
Core evidence, 1(1), 35-42 (2005-01-01)
Restless legs syndrome (RLS) affects 5-15% of adults, but is often unrecognized and consequently misdiagnosed. The International Restless Legs Scale (IRLS) has been developed and validated to assess the severity of RLS. Currently, the most common treatment for RLS is
Haritz Jiménez-Urbieta et al.
Neurobiology of aging, 75, 126-135 (2018-12-21)
Treatment with dopaminergic agonists such as pramipexole (PPX) contributes to the development of impulse control disorders (ICDs) in patients with Parkinson's disease (PD). As such, animal models of abnormal impulse control in PD are needed to better study the pathophysiology

Artigos

We offer many products related to dopamine receptors for your research needs.

Discover Bioactive Small Molecules for ADME/Tox

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica